Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Standard vs Low Dose Rituximab with Alemtuzumab in Elderly CLL
NCT01013961Phase 2Terminated
- Sponsor
- ECOG-ACRIN Cancer Research Group
- Start
- Apr 2011
- Primary completion
- Apr 2015
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of rituximab in chronic lymphocytic leukemia (CLL), sponsored by ECOG-ACRIN Cancer Research Group. Started Apr 2011; status: terminated.
02
Drugs
rituximab
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT01013961.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01013961.